Hussman Strategic Advisors’s Acorda Therapeutics ACOR Stock Holding History

Hussman Strategic Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-625	Closed	-$1.47M	–	281
2018 Q3	$1.47M	Hold	625	–	–	0.43%	105
2018 Q2	$2.15M	Buy	625 +208	+50%	+$637K	0.58%	74
2018 Q1	$1.18M	Buy	+417	New	+$1.25M	0.33%	115
2016 Q3	–	Sell	-625	Closed	-$1.91M	–	218
2016 Q2	$1.91M	Sell	625 -1,458	-70%	-$4.74M	0.29%	96
2016 Q1	$6.61M	Buy	2,083 +1,250	+150%	+$5.19M	0.88%	47
2015 Q4	$4.28M	Buy	833 +375	+82%	+$1.64M	0.61%	66
2015 Q3	$1.46M	Sell	458 -675	-60%	-$2.62M	0.18%	128
2015 Q2	$4.53M	Sell	1,133 -617	-35%	-$2.38M	0.52%	75
2015 Q1	$6.99M	Buy	+1,750	New	+$8.02M	0.73%	53

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hussman Strategic Advisors's ACOR Position: Q4 2018 in Review

Hussman Strategic Advisors sold out of Acorda Therapeutics (ACOR) in Q4 2018, closing a stake of 625 shares — an estimated $1.47M sold.

Hussman Strategic Advisors first reported a position in ACOR in Q1 2015 and held it in 9 quarters. The position peaked at $6.99M in Q1 2015. 179 funds tracked by Wall St. Rank hold ACOR as of Q4 2018.

Hussman Strategic Advisors reported no remaining Acorda Therapeutics position as of Q4 2018 after selling out during the quarter.
Hussman Strategic Advisors sold 625 Acorda Therapeutics shares in Q4 2018, an estimated $1.47M.
Hussman Strategic Advisors first reported a position in Acorda Therapeutics in Q1 2015 and held it in 9 quarters.
Hussman Strategic Advisors's Acorda Therapeutics position peaked at $6.99M in Q1 2015.
179 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2018.

Based on Hussman Strategic Advisors's 13F filing for Q4 2018, filed 1 Feb 2019.